|
1
|
Reske SN: PET and PET-CT of malignant
tumors of the exocrine pancreas. Radiologe. 49:131–136. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
3
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar
|
|
4
|
Tempero MA, Behrman S, Ben-Josef E, et al:
National Comprehensive Cancer Network. Pancreatic adenocarcinoma:
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
3:598–626. 2005.
|
|
5
|
Bredel M: Anticancer drug resistance in
primary human brain tumors. Brain Res Brain Res Rev. 35:161–204.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
El Maalouf G, Le Tourneau C, Batty GN,
Faivre S and Raymond E: Markers involved in resistance to
cytotoxics and targeted therapeutics in pancreatic cancer. Cancer
Treat Rev. 35:167–174. 2009.PubMed/NCBI
|
|
7
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
8
|
Shuangsuo D, Zhengguo Z, Yunru C, Xin Z,
Baofeng W, Lichao Y and Yan’an C: Inhibition of the replication of
hepatitis B virus in vitro by emodin. Med Sci Monit. 12:BR302–306.
2006.PubMed/NCBI
|
|
9
|
Semple SJ, Pyke SM, Reynolds GD and Flower
RL: In vitro antiviral activity of the anthraquinone chrysophanic
acid against poliovirus. Antiviral Res. 49:169–178. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li HL, Chen HL, Li H, et al: Regulatory
effects of emodin on NF-kappaB activation and inflammatory cytokine
expression in RAW 264.7 macrophages. Int J Mol Med. 116:41–47.
2005.PubMed/NCBI
|
|
11
|
Chen RF, Shen YC, Huang HS, et al:
Evaluation of the anti-inflammatory and cytotoxic effects of
anthraquinones and anthracenes derivatives in human leucocytes. J
Pharm Pharmacol. 56:915–919. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin SZ, Chen KJ, Tong HF, Jing H, Li H and
Zheng SS: Emodin attenuates acute rejection of liver allografts by
inhibiting hepatocellular apoptosis and modulating the Th1/Th2
balance in rats. Clin Exp Pharmacol Physiol. 37:790–794.
2010.PubMed/NCBI
|
|
13
|
Huang XZ, Wang J, Huang C, Chen YY, Shi
GY, Hu QS and Yi J: Emodin enhances cytotoxicity of
chemotherapeutic drugs in prostate cancer cells: the mechanisms
involve ROS-mediated suppression of multidrug resistance and
hypoxia inducible factor-1. Cancer Biol Ther. 7:468–475. 2008.
View Article : Google Scholar
|
|
14
|
Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC,
Cheng CM and Lin YW: Suppression of ERCC1 and Rad51 expression
through ERK1/2 inactivation is essential in emodin-mediated
cytotoxicity in human non-small cell lung cancer cells. Biochem
Pharmacol. 79:655–664. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang Q, Lu G, Shen HM, Chung MC and Ong
CN: Anti-cancer properties of anthraquinones from rhubarb. Med Res
Rev. 27:609–630. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gui M, Zhang YF, Xiao ZY, et al:
Inhibitory effect of emodin on tissue inhibitor of
metalloproteinases-1 (TIMP-1) expression in rat hepatic stellate
cells. Dig Dis Sci. 52:200–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Liu P, Mao H, Wang A and Zhang X:
Emodin sensitizes paclitaxel-resistant human ovarian cancer cells
to paclitaxel-induced apoptosis in vitro. Oncol Rep. 21:1605–1610.
2007.PubMed/NCBI
|
|
18
|
Chen H, Wei W, Guo Y, et al: Enhanced
effect of gemcitabine by emodin against pancreatic cancer in vivo
via cytochrome C-regulated apoptosis. Oncol Rep. 25:1253–1261.
2011.PubMed/NCBI
|
|
19
|
Lin SY, Lai WW, Ho CC, et al: Emodin
induces apoptosis of human tongue squamous cancer SCC-4 cells
through reactive oxygen species and mitochondria-dependent
pathways. Anticancer Res. 29:327–335. 2009.
|
|
20
|
Baldwin AS: Control of oncogenesis and
cancer therapy resistance by the transcription factor NF-kappaB. J
Clin Invest. 107:241–246. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weldon CB, Burow ME, Rolfe KW, et al:
NF-kappa B-mediated chemoresistance in breast cancer cells.
Surgery. 130:143–150. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang CY, Cusack JC Jr, Liu R and Baldwin
AS Jr: Control of inducible chemoresistance: enhanced anti-tumor
therapy through increased apoptosis by inhibition of NF-kappaB. Nat
Med. 5:412–417. 2009.PubMed/NCBI
|
|
23
|
Nakanishi C and Toi M: Nuclear
factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat
Rev Cancer. 5:297–309. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH:
Tetramethylpyrazine reverses multidrug resistance in breast cancer
cells through regulating the expression and function of
P-glycoprotein. Med Oncol. 29:534–538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Banerjee S, Wang Z, Kong D and Sarkar FH:
3,3′-Diindolyl-methane enhances chemosensitivity of multiple
chemotherapeutic agents in pancreatic cancer. Cancer Res.
69:5592–5600. 2009.
|
|
26
|
Bentires-Alj M, Barbu V, Fillet M, et al:
NF-kappaB transcription factor induces drug resistance through MDR1
expression in cancer cells. Oncogene. 22:90–97. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
König J, Hartel M, Nies AT, et al:
Expression and localization of human multidrug resistance protein
(ABCC) family members in pancreatic carcinoma. Int J Cancer.
115:359–367. 2005.PubMed/NCBI
|
|
28
|
Hao Z, Li X, Qiao T, Du R, Hong L and Fan
D: CIAPIN1 confers multidrug resistance by upregulating the
expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol
Ther. 5:261–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen C, Shen HL, Yang J, Chen QY and Xu
WL: Preventing chemoresistance of human breast cancer cell line,
MCF-7 with celecoxib. J Cancer Res Clin Oncol. 137:9–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leonessa F and Clarke R: ATP binding
cassette transporters and drug resistance in breast cancer. Endocr
Relat Cancer. 10:43–73. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hannun YA: Apoptosis and the dilemma of
cancer chemotherapy. Blood. 89:1845–1853. 1997.PubMed/NCBI
|
|
32
|
Duffy MJ, O’Donovan N, Brennan DJ,
Gallagher WM and Ryan BM: Survivin: a promising tumor biomarker.
Cancer Lett. 249:49–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cohen C, Lohmann CM, Cotsonis G, Lawson D
and Santoianni R: Survivin expression in ovarian carcinoma:
correlation with apoptotic markers and prognosis. Mod Pathol.
16:574–583. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zaffaroni N and Daidone MG: Survivin
expression and resistance to anticancer treatments: perspectives
for new therapeutic interventions. Drug Resist Updat. 5:65–72.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Connolly K, Mitter R, Muir M, Jodrell D
and Guichard S: Stable XIAP knockdown clones of HCT116 colon cancer
cells are more sensitive to TRAIL, taxanes and irradiation in
vitro. Cancer Chemother Pharmacol. 64:307–316. 2009. View Article : Google Scholar : PubMed/NCBI
|
